CB-839 + Cabozantinib + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Renal Cell Carcinoma
Conditions
Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Trial Timeline
Apr 24, 2018 → Jul 16, 2021
NCT ID
NCT03428217About CB-839 + Cabozantinib + Placebo
CB-839 + Cabozantinib + Placebo is a phase 2 stage product being developed by Calithera Biosciences for Advanced Renal Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03428217. Target conditions include Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Renal Cell Carcinoma were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03428217 | Phase 2 | Completed |
Competing Products
20 competing products in Advanced Renal Cell Carcinoma